感染病临床试验资助与地域分布
该研究对2014–2023年发表于十本高影响力英文期刊的1343项感染病随机对照试验进行二次分析,提取资助来源与研究地点并按世界银行收入分类。结果显示资助方82.7%来自高收入国家,而研究地点在高收入国家占61.9%,低中收入国家存在疾病研究空白。
要点
- 感染病RCT资助高度集中于高收入国家,82.7%资助方来自高收入国家。
- 研究地点分布较资助更分散,高收入国家占61.9%,低收入国家占6.2%。
- 低中收入国家在重症、细菌感染、性传播感染等疾病领域研究不足。
核心结论
- 十本高影响力英文期刊发表的感染病RCT中,资助来源与研究地点地理分布不均衡,资助主要来自高收入国家。
研究设计与样本
- 对已发表系统综述的1343项感染病随机对照试验(2014–2023年,十本高影响力英文综合医学与感染病期刊)进行二次分析,按世界银行收入分类分析资助来源与研究地点。
主要发现
- 1343项试验中1326项披露资助来源(98.7%),其中研究者发起的试验772/1326(58.2%)。
- 美国政府为最大资助方(366/1326,27.6%),美国国立卫生研究院(NIH)资助258/1326(19.5%)项试验。
- 共1808个独立资助方,高收入国家1496/1808(82.7%),中高收入130/1808(7.2%),中低收入35/1808(1.9%),低收入8/1808(0.4%)。
- 重症监护、细菌感染、性传播感染、肝炎、流感及COVID-19相关试验在低收入环境中代表性不足。
临床怎么用
- 阅读感染病RCT证据时需关注资助来源与研究地点,评估结果对低中收入国家人群的外推性。
- 认识到低收入环境中重症、细菌感染、性传播感染、肝炎、流感及COVID-19相关RCT证据可能不足。
局限性
- 本研究为对已发表系统综述的二次分析,仅纳入十本选定的高影响力英文期刊,可能限制结果外推。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to map the funding flows in infectious disease randomized clinical trials (RCTs) by examining the relationships between funding sources and trial locations in high-impact journals. METHODS: We conducted a secondary analysis of a previously published systematic review of 1343 infectious disease RCTs published (2014-2023) in ten selected high-impact English-language general medicine and infectious disease journals. Funding source, study site, and disease focus were extracted using a standardized data extraction form and analysed by country income level using World Bank classifications. Geographical distributions of funding and study sites were visualized using global heat maps. Funding flows between country income groups were visualized using a Sankey plot. RESULTS: Of the 1343 trials, 1326 disclosed the funding source (98.7%). Most trials identified in this review were investigator-initiated (772/1326, 58.2%), with the U.S. government as the largest contributing funder (366/1326, 27.6%), and the National Institutes of Health specifically involved in funding 258 of 1326 (19.5%) of trials. When disaggregated, there was a total of 1808 unique funders. These overwhelmingly originated from high-income countries (1496/1808, 82.7%) compared with upper-middle-income (130/1808, 7.2%), low-middle-income (35/1808, 1.9%), and low-income (8/1808, 0.4%) countries. In contrast, the 4606 disaggregated locations of study by country were more distributed across income levels: high-income (2521/4606, 61.9%), upper-middle-income (918/4606, 22.5%), lower-middle-income (360/4606, 8,8%), and low-income (253/4606, 6.2%) countries. Disease focus varied geographically; trials focusing on critical care, bacterial infections, sexually transmitted infections, hepatitis, influenza, and COVID-19 were underrepresented in low-income settings. CONCLUSIONS: Our study reveals skewed geographical and funding distributions in the global landscape of infectious disease RCTs published in these ten selected English-language high-impact journals. As key funders reduce funding internationally, the impact on the research landscape may disproportionately affect lower-middle-income countries. Further efforts should be made to build sustainable funding models and research capacity in lower-middle-income countries.
引用
- Moffroid H, Charani E, Blagojevic C, et al. Funding and geographical distribution of clinical trials in infectious diseases. Clin Microbiol Infect. 2025. PMID: 41022352. doi:10.1016/j.cmi.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。